… It was the phase 2/3 MOVe-OUT clinical trial in non-hospitalized … The present study included
590 adult patients from 13 centers, … treated with molnupiravir (MOL) or without any antiviral …

… We included adult patients with mild-to-moderate SARS-CoV-2 infection (confirmed by RT-PCR)
at high risk for disease progression, who were treated as outpatients with a 3-day …

… molnupiravir and nirmatrelvir–ritonavir are both oral drugs, there have been concerns about
teratogenicity and mutagenicity with molnupiravir.… ‐risk, nonhospitalized adults with Covid‐19…

… Molnupiravir was based on a phase 3 trial on the efficacy and safety of molnupiravir
treatment … or symptoms of COVID-19 in nonhospitalized, unvaccinated adults with mild-to-moderate …

… 7,013 non-hospitalized adult COVID-19 patients infected between 16 December 2021 and
22 April 2022—4973 controls against 2040 patients treated either with Molnupiravir (N = 3591…

… This randomized, placebo (Plb)-controlled, double-blind, multi-site decentralized clinical
trial enrolled non-hospitalized adults with confirmed SARS-CoV-2 infection and six or fewer …

… nirmatrelvir/ritonavir and molnupiravir before hospitalisation on subsequent … molnupiravir
are effective in reducing hospitalisation and mortality rates in the setting of outpatient treatment …

… Development (EIDD), molnupiravir is active against influenza … EIDD developed molnupiravir
for the treatment of pathogenic … 2–3 placebo-controlled trial of molnupiravir that may begin to …

… proof that oral Molnupiravir is effective for the treatment of … non-hospitalized unvaccinated
adults, the FDA and NIH COVID-19 treatment guideline both recommended using Molnupiravir …

… use of molnupiravir, the first antiviral drug against SARS-CoV-2 available to us, in the treatment
of … All patients received molnupiravir (800 mg twice daily). Blood chemistry checks were …